TOSS, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.248
AS - Asia 8.062
EU - Europa 5.776
SA - Sud America 1.306
AF - Africa 250
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 11
Totale 28.696
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.925
SG - Singapore 2.397
CN - Cina 1.915
IT - Italia 1.603
GB - Regno Unito 1.089
VN - Vietnam 1.053
HK - Hong Kong 971
BR - Brasile 967
DE - Germania 557
SE - Svezia 547
IE - Irlanda 341
FI - Finlandia 329
RU - Federazione Russa 299
KR - Corea 273
FR - Francia 262
BD - Bangladesh 250
IN - India 242
ID - Indonesia 189
CA - Canada 153
TR - Turchia 123
UA - Ucraina 123
AR - Argentina 111
MX - Messico 109
IQ - Iraq 96
JP - Giappone 96
NL - Olanda 95
BG - Bulgaria 91
ES - Italia 70
PL - Polonia 68
ZA - Sudafrica 67
CO - Colombia 56
EC - Ecuador 56
PK - Pakistan 54
MY - Malesia 49
EG - Egitto 46
AT - Austria 44
TW - Taiwan 44
LT - Lituania 43
AE - Emirati Arabi Uniti 39
AU - Australia 38
MA - Marocco 35
VE - Venezuela 33
SA - Arabia Saudita 29
CL - Cile 28
PH - Filippine 28
IR - Iran 27
UZ - Uzbekistan 27
KE - Kenya 24
PY - Paraguay 24
BE - Belgio 23
JO - Giordania 20
CZ - Repubblica Ceca 18
AZ - Azerbaigian 16
DK - Danimarca 16
MD - Moldavia 15
NP - Nepal 15
GR - Grecia 14
SI - Slovenia 14
TH - Thailandia 14
TN - Tunisia 14
CH - Svizzera 13
BO - Bolivia 12
DZ - Algeria 12
IL - Israele 12
PA - Panama 12
RO - Romania 12
AL - Albania 11
HU - Ungheria 11
DO - Repubblica Dominicana 10
PE - Perù 10
SY - Repubblica araba siriana 10
HR - Croazia 9
KG - Kirghizistan 9
NO - Norvegia 9
CR - Costa Rica 8
JM - Giamaica 8
KZ - Kazakistan 8
LB - Libano 8
LV - Lettonia 8
CI - Costa d'Avorio 7
CY - Cipro 7
MT - Malta 7
OM - Oman 7
UY - Uruguay 7
AO - Angola 6
BH - Bahrain 6
BY - Bielorussia 6
ET - Etiopia 6
GE - Georgia 6
PT - Portogallo 6
RS - Serbia 6
EU - Europa 5
GH - Ghana 5
NZ - Nuova Zelanda 5
SN - Senegal 5
XK - ???statistics.table.value.countryCode.XK??? 5
CG - Congo 4
HN - Honduras 4
MK - Macedonia 4
PS - Palestinian Territory 4
Totale 28.624
Salva come PNG Salva come JPEG
Città #
Ashburn 1.669
Singapore 1.393
Santa Clara 1.300
Fairfield 1.115
Hong Kong 943
Chandler 751
San Jose 688
Hefei 654
Woodbridge 536
Seattle 474
Houston 428
Southend 395
Cambridge 388
Council Bluffs 378
Beijing 359
Dublin 336
Nyköping 336
Ho Chi Minh City 334
Wilmington 331
London 328
Los Angeles 268
Helsinki 260
Dallas 258
Seoul 254
Hanoi 245
New York 242
Dearborn 212
Ann Arbor 206
Modena 197
The Dalles 163
Milan 160
Chicago 154
Jakarta 138
Lauterbourg 122
San Diego 107
Jacksonville 105
Bologna 95
Princeton 95
São Paulo 89
Sofia 88
Moscow 86
Munich 86
Tokyo 81
Boardman 79
Shanghai 76
Frankfurt am Main 74
Orem 72
Buffalo 69
Rome 69
Salt Lake City 63
Bremen 58
Eugene 52
Izmir 52
Baghdad 51
Da Nang 50
Haiphong 50
Warsaw 50
Redwood City 49
Fremont 44
Manchester 41
Nuremberg 39
Reggio Emilia 39
Columbus 38
Dong Ket 38
Kent 38
Montreal 37
Johannesburg 36
Phoenix 36
Mexico City 35
Brooklyn 34
Toronto 34
Chennai 33
Guangzhou 32
Atlanta 31
Belo Horizonte 31
Portsmouth 31
Redondo Beach 31
Rio de Janeiro 31
Stockholm 31
Denver 30
Lappeenranta 30
Mumbai 30
Parma 30
San Giuliano Milanese 28
Düsseldorf 27
Florence 27
Poplar 27
Dhaka 26
Falls Church 25
Miano 24
Turku 24
Sydney 23
Tashkent 23
Vienna 23
Brasília 22
Lawrence 22
Madrid 22
Miami 22
Amsterdam 21
Asyut 21
Totale 19.028
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 606
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 471
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 471
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 451
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 416
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 383
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 383
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 361
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 339
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 338
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 337
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 335
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 332
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 327
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 324
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 319
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 303
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 299
NUT midline carcinoma of the head and neck: current perspectives 295
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 294
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 288
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 288
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 288
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 284
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 283
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 283
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 281
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 279
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 279
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 277
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 277
Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study 272
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 270
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 269
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 267
Hereditary ovarian cancers: State of the art 266
Combined hormonal contraceptives in BRCA gene mutation carriers: why not? 262
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 260
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 258
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 252
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 251
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 249
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 249
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 248
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 246
Characterization of new ATM deletion associated with hereditary breast cancer 240
Chemoprevention strategies for high risk women 238
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 235
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 235
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 235
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 235
Twenty-years experience with de novo metastatic breast cancer 234
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 233
The role of exosomes in breast cancer diagnosis 233
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 231
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study 230
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 226
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 222
Radiological screening programs for women at high risk of developing breast cancer 220
Breast ultrasound in high-risk women 218
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 217
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial 216
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 216
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis 216
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 215
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 214
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 212
Molecular characterization and targeted therapeutic approaches in breast cancer 211
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 209
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 206
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 198
PARP inhibitors for the treatment of ovarian cancer 196
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 193
Management of PALB2-associated breast cancer: A literature review and case report 192
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 188
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 186
Personalized Systemic Therapies in Hereditary Cancer Syndromes 183
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 182
Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less 182
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 182
COVID-related disruption in mammographic screening: a year later. 181
Occult breast cancer: the uncommon presentation of a common disease 180
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 179
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 171
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 170
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 168
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 166
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 165
PARP Inhibitors for Breast Cancer Treatment A Review 161
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 161
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 161
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group 160
LOW-FREQUENCY ALLELE VARIANTS IN NGS MULTI-GENE PANELS FOR HEREDITARY CANCER TESTING: ARTIFACTS, CHIP OR MOSAICS? MANAGING THE RESULTS IN THE LABORATORY ROUTINE 159
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 157
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer 156
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic 156
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 153
The spectrum of fancm protein truncating variants in European breast cancer cases 152
Talking about sex: erectile dysfunction in the oncology patient 151
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 151
Totale 24.847
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.033
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.033
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021192 0 0 0 0 0 0 0 0 0 0 0 192
2021/20221.887 123 164 141 82 68 133 90 102 250 164 336 234
2022/20232.396 268 301 169 192 225 259 48 180 526 35 98 95
2023/20241.714 92 92 97 175 260 144 216 219 66 63 108 182
2024/20255.776 140 45 112 298 978 752 572 353 675 374 626 851
2025/202612.054 870 457 1.111 1.368 1.490 810 1.547 698 1.211 1.241 1.045 206
Totale 28.960